Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy

Front Genet. 2024 Apr 11:15:1364742. doi: 10.3389/fgene.2024.1364742. eCollection 2024.

Abstract

The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) mediated Cas9 nuclease system has been extensively used for genome editing and gene modification in eukaryotic cells. CRISPR/Cas9 technology holds great potential for various applications, including the correction of genetic defects or mutations within the human genome. The application of CRISPR/Cas9 genome editing system in human disease research is anticipated to solve a multitude of intricate molecular biology challenges encountered in life science research. Here, we review the fundamental principles underlying CRISPR/Cas9 technology and its recent application in neurodegenerative diseases, cardiovascular diseases, autoimmune related diseases, and cancer, focusing on the disease modeling and gene therapy potential of CRISPR/Cas9 in these diseases. Finally, we provide an overview of the limitations and future prospects associated with employing CRISPR/Cas9 technology for diseases study and treatment.

Keywords: CRISPR/Cas9; autoimmune-related diseases; cancer; cardiovascular diseases; diseases modeling; gene therapy; neurodegenerative diseases.

Publication types

  • Review

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (82260138, 82260327); Natural Science Foundation of Inner Mongolia (2022QN08022); The Scientific Research Project of Colleges and Universities, Inner Mongolia Department of Education (NJZZ22678, NJZZ23014); The Inner Mongolia Health Commission’s Medical and Health Science and Technology Program (Class A) (202201267).